Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9769323 | European Journal of Medicinal Chemistry | 2005 | 6 Pages |
Abstract
Six new galactoglycerolipid analogs, in which one or two 4-methylpentanoyl or trans-2-butenoyl groups are linked to the 2-O-β-d-galactosylglycerol skeleton, were tested for their anti-tumor-promoting activity using a short-term in vitro assay for Epstein-Barr virus early antigen (EBV-EA) activation. All these compounds were more active than their linear or saturated reference compounds in inhibiting the EBV activation promoted by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA), the diester 1-O-(4-methylpentanoyl)-2-O-[6-O-(4-methylpentanoyl)-β-d-galactopyranosyl]-sn-glycerol resulting the most active glycoglycerolipid analog till now tested. Four compounds (three butenoates and one 4-methylpentanoate), when tested in the in vivo two-stage carcinogenesis test, exhibited also inhibitory effects on mouse skin tumor promotion.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Diego Colombo, Laura Franchini, Lucio Toma, Fiamma Ronchetti, Nami Nakabe, Takako Konoshima, Hoyoku Nishino, Harukuni Tokuda,